Amylin Pharmaceuticals is focused on metabolic diseases such as diabetes and obesity. The company has two products on the market, Symlin and Byetta, both approved in the US since 2005. Byetta, the first ever approved glucagon-like peptide-1 (GLP-1) analog, reduces blood sugar and weight in diabetic patients and is partnered with Eli Lilly. Amylin is also developing a long-acting GLP-1 analog (Bydureon), which only has to be injected once a week.

In October 2010 Amylin received a complete response letter from the FDA for Bydureon, stating that another short study including measuring heart rhythm at super therapeutic doses is requested. Another product under regulatory review is Metreleptin, which is being developed for a rare disease called lipodystrophy where normal fat tissue is lost and fat is deposited in various organs. Additionally, Metreleptin in combination with another compound called pramlintide is being developed as a treatment for obesity, where promising Phase II data has been shown. Both indications are partnered with Takeda.

Back